Yu-Wen Wen

8PUBLICATIONS
26CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursDisease surveillancePredictive and prognostic markersCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 15, 2026
Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma.

Szu-Ting Chiang, Chen-Han Chueh, Yu-Wen Wen

|Oct 22, 2025
Prognostic Significance of Circulating Tumor Cells in Patients with Esophageal Cancer Who Attained Pathological Complete Response after Neoadjuvant Therapy.

Chia-Hsun Hsieh, Chuan Cheng, Yu-Wen Wen

|Sep 28, 2024
Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents.

Yu-Ting Kao, Yen-Chun Liu, Ya-Ting Cheng

|Jun 24, 2024
The 2017 Women's Health Initiative study and use of hormone therapy: an emulated repeated cross-sectional study.

Chen-Han Chueh, Pei-Kuan Ho, Wai-Hou Li

|Mar 28, 2024
Incidence and Predictors of Textbook Outcome after Minimally Invasive Esophagectomy for Cancer: A Two-Center Study.

Evangelos Tagkalos, Peter Grimminger, Xing Gao

|Dec 27, 2022
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy.

Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen

Pageof 2

Frequent Collaborators

3 joint publications

Chen-Han Chueh

3 joint publications

Yi-Wen Tsai

2 joint publications

Li-Ang Lee

2 joint publications

Ming-Neng Shiu